” Federal health regulators on Tuesday approved a highly anticipated medicine from Pfizer Inc. to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs. The Food and Drug Administration approved Ibrance for women who have tumors that do not contain a protein known as HER-2 and have receptors for the hormone estrogen.
Are you up for a challenge?
